Viewing Study NCT03727750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:54 PM
Ignite Modification Date: 2026-01-25 @ 3:11 PM
Study NCT ID: NCT03727750
Status: COMPLETED
Last Update Posted: 2022-03-25
First Post: 2018-09-28
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
Sponsor: Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None ECG View
None Pharmacokinetics View
None Safety View
Keywords:

Keywords

Keyword Brief Keyword Text View
None gemtuzumab ozogamicin View
None Mylotarg View
None QT interval prolongation View
None Pharmacokinetics View
None Safety View
None Veno-occlusive disease View
None Anti-drug antibody View